SAN DIEGO, Feb. 16, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced Scott H.
Bice, Phillip M. Schneider, and
Christine A. White, M.D. have
indicated that they will be retiring from the Board of Directors at
the time of Arena's next annual stockholders' meeting, which is
expected to held in June 2018.
"I would like to thank Scott, Phil and Christine for their
numerous contributions and guidance over the past ten and more
years," said Dr. Tina S. Nova, Chair
of the Board. "Their perspectives and insights have helped shape
Arena, navigate difficult times, and position us well for the
future."
"We appreciate the dedication, support and contributions of
Scott, Phil and Christine in helping us to build a strong
foundation," added Amit D. Munshi,
President and CEO of Arena. "We are excited about the continued
transformation of Arena that all directors and management have been
implementing and the opportunities ahead, including multiple
significant catalysts in the coming quarters around our potentially
first- or best-in-class clinical stage programs."
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on developing novel, small molecule drugs with optimized
receptor pharmacology and pharmacokinetics designed to deliver
broad clinical utility across several therapeutic areas. Arena's
proprietary pipeline includes potentially first- or best-in-class
programs. The most advanced investigational clinical programs
are ralinepag (APD811), which will be commencing a Phase 3 program
for pulmonary arterial hypertension (PAH), and etrasimod (APD334),
which is in Phase 2 for a broad range of immune and inflammatory
conditions. Arena is also evaluating APD371 in Phase 2 for
the treatment of pain associated with Crohn's disease. In addition,
Arena has collaborations with the following pharmaceutical
companies: Everest Medicines Limited (ralinepag and etrasimod in
Greater China and select Asian
countries), Axovant Sciences GmbH (nelotanserin - Phase 2),
Boehringer Ingelheim International GmbH (undisclosed target -
preclinical), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® - marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "will," "expected," "future,"
"opportunities," "focused on," "designed to," "potentially," "may,"
or words of similar meaning, or by the fact that they do not relate
strictly to historical or current facts. Such forward-looking
statements include statements about Arena's upcoming annual
stockholders' meeting, our position for the future, opportunities,
catalysts, programs (including their potential to be first- or
best-in-class), focus and collaborations. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include
that clinical programs may not proceed at the time or in the manner
expected or at all, as well as those factors disclosed in Arena's
filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-changes-to-board-of-directors-300599883.html
SOURCE Arena Pharmaceuticals, Inc.